Results 11 to 20 of about 2,816 (233)

Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90

EJNMMI Physics, 2022
Background Based on theoretical and preclinical results, terbium-161 may be a valid alternative to lutetium-177 and yttrium-90 in radionuclide therapies.
Jens Hemmingsson, Johanna Svensson, Nicholas P. van der Meulen, Cristina Müller, Peter Bernhardt   +4 more
doaj   +1 more source

AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer

European Urology Open Science, 2023
Lutetium-177 prostate-specific membrane antigen radioligands (177Lu-PSMA) are new therapeutic agents for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Jan Vanwelkenhuyzen, Eva Van Bos, Siska Van Bruwaene, Karl Lesage, Alex Maes, Sezgin Üstmert, Filip Lavent, Laurence Beels, Henrik Grönberg, Piet Ost, Johan Lindberg, Bram De Laere   +11 more
doaj   +1 more source

Radioligand Therapy with [¹⁷⁷Lu]Lu-DOTA-TATE or [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade

Pharmaceuticals, 2023
Background: Neuroendocrine neoplasms (NENs) are a rare group of tumors with a different clinical course, prognosis and location. Radioligand therapy (RLT) can be used as a first or second line of treatment. It is registered in gastroenteropancreatic NENs
Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Adrianna Mróz, Wawrzyniec Żmudzki, Grzegorz Kamiński   +7 more
doaj   +1 more source

Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics [PDF]

, 2019
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR ...
Beattie, Bradley J., Beattie, Kai A., Elgqvist, Jörgen, Eriksson, Sophie E., Larsson, Erik, Strand, Sven-Erik, Thorek, Daniel L. J., Timmermand, Oskar Vilhelmsson, Tran, Thuy A., Ulmert, David, Örbom, Anders   +10 more
core   +2 more sources

Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application

EJNMMI Radiopharmacy and Chemistry, 2023
Background 177Lu-radiopharmaceuticals are routinely used for the treatment of various tumor entities. The productions of radiopharmaceuticals follow strict good-manufacturing practice guidelines and synthesis optimizations thereof have a strong impact on
Aylin Cankaya, Matthias Balzer, Holger Amthauer, Winfried Brenner, Sarah Spreckelmeyer   +4 more
doaj   +1 more source

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources

Targeted radiotherapy of neuroblastoma: future directions [PDF]

, 2017
No abstract ...
Gaze, Mark N., Mairs, Robert, Nile, Donna L., Rae, Colin, Tesson, Mathias   +4 more
core   +2 more sources

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies [PDF]

, 2015
Background: Successful treatments of patients with somatostatin receptor (SSTR)-overexpressing neuroendocrine tumours (NET) comprise somatostatin-analogue lutetium-177-labelled octreotate (177Lu-TATE) treatment, also referred to as peptide receptor ...
Bernsen, M.R. (Monique), Bison, S.M. (Sander), Bol, K. (Karin), Groen, H.C. (Harald), Haeck, J.C. (Joost), Jong, M. (Marion) de, Koelewijn, S. (Stuart), Melis, M.L. (Marleen), Veenland, J.F. (Jifke)   +8 more
core   +1 more source

DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy [PDF]

, 2013
Key biologic effects of the alpha-particle emitter Actinium-225 in comparison to beta-particle emitter Lutetium-177 labeled somatostatin analogue DOTATOC in vitro and in vivo were studied to evaluate the significance of H2AX-foci formation and its ...
BRUCHERTSEIFER Frank, FAHRER Jörg, FOTTNER C., GRAF Franziska, HUELSENBECK Johannes, KAINA B, MAUS Stephan, MIEDERER Matthias, MORGENSTERN Alfred, SCHRECKENBERGER M, VENKATACHALAM S., WEBER M.m.   +11 more
core   +1 more source

Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153 [PDF]

, 2016
PurposeThe present review article aims to provide an overview of the available radionuclides for palliative treatment of bone metastases beyond 89Sr and 153Sm.
Adriana Alexandre S. Tavares, Francisco D. C. Guerra Liberal, João Manuel R. S. Tavares   +2 more
core   +1 more source